Video
Insight for practicing clinicians on targeted radionuclide therapies for prostate cancer
Author(s):
Video Player is loading.
Scott T. Tagawa, MD, MS, FACP, discusses the current state of targeted radionuclide therapies in the prostate cancer paradigm and previews what’s on the horizon for the burgeoning field of theranostics. Tagawa is a professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital
Related Videos
PSMA PET and treatment intensification in mHSPC
Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
Amar Kishan, MD, on implications of MIRAGE trial data
Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
Amar Kishan, MD, outlines the rationale for the MIRAGE trial
Michael Cookson, MD, on potential future applications of PSMA-PET
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
Michael Cookson, MD, on challenges with PSMA-PET imaging
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
Expert: PSMA-PET should be considered at lower PSA levels
Related Content
